Patents by Inventor Jianrong Lu

Jianrong Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cleaning system and cleaning method
    Patent number: 11940811
    Abstract: A cleaning system and a cleaning method configured for cleaning task of solar panels are provided. The cleaning system includes an operation region, cleaning robots, shuttle robots, and a data processing system. The cleaning method includes a first carrying step, a cleaning step, and a second carrying step.
    Type: Grant
    Filed: November 9, 2019
    Date of Patent: March 26, 2024
    Assignee: SUZHOU RADIANT PHOTOVOLTAIC TECHNOLOGY CO., LTD.
    Inventors: Jianrong Xu, Jianxiang Lu, Fei Xu
  • Modulating the Activity of Nuclear Receptors in Order to Treat Hypoxia-Related Disorders
    Publication number: 20100210735
    Abstract: The subject invention provides methods for treating hypoxia-related conditions by modulating the activity of certain nuclear receptors. Specifically exemplified herein are materials and methods for treating cancer and other pathological conditions involving hypoxia and/or abnormal or excessive neovascularization.
    Type: Application
    Filed: August 6, 2008
    Publication date: August 19, 2010
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Jianrong Lu
  • Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
    Publication number: 20090087412
    Abstract: The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
    Type: Application
    Filed: September 2, 2008
    Publication date: April 2, 2009
    Inventors: Eric N. Olson, Jianrong Lu, Timothy McKinsey
  • Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
    Patent number: 7420100
    Abstract: The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: September 2, 2008
    Assignee: Board of Regents, The University of Texas System
    Inventors: Eric N. Olson, Jianrong Lu, Timothy McKinsey
  • Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
    Publication number: 20050106654
    Abstract: The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
    Type: Application
    Filed: August 8, 2003
    Publication date: May 19, 2005
    Inventors: Eric Olson, Jianrong Lu, Timothy McKinsey
  • Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
    Patent number: 6632628
    Abstract: The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: October 14, 2003
    Assignee: Board of Regents, The University of Texas System
    Inventors: Eric N. Olson, Jianrong Lu, Timothy McKinsey